[go: up one dir, main page]

ES2159624T3 - Toxinas botulinicas para el tratamiento de la hiperhidrosis. - Google Patents

Toxinas botulinicas para el tratamiento de la hiperhidrosis.

Info

Publication number
ES2159624T3
ES2159624T3 ES95906674T ES95906674T ES2159624T3 ES 2159624 T3 ES2159624 T3 ES 2159624T3 ES 95906674 T ES95906674 T ES 95906674T ES 95906674 T ES95906674 T ES 95906674T ES 2159624 T3 ES2159624 T3 ES 2159624T3
Authority
ES
Spain
Prior art keywords
treatment
botulinic
hyperhydrosis
toxins
botulinum toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95906674T
Other languages
English (en)
Inventor
K Roger Aoki
Michael W Grayston
Steven R Carlson
Judith M Leon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22634387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2159624(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Application granted granted Critical
Publication of ES2159624T3 publication Critical patent/ES2159624T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SUMINISTRA UN METODO PARA ALIVIAR EL DOLOR ASOCIADO CON CONTRACCIONES MUSCULARES, UN COMPUESTO Y UN METODO DE TRATAMIENTO DE CONDICIONES TALES COMO LAS SECRECIONES COLINERGICAS, CONTROLADAS QUE INCLUYEN LA SUDORACION EXCESIVA, LAS SECRECIONES LACRIMALES Y MUCOSALES Y UN METODO PARA EL TRATAMIENTO DE ENFERMEDADES DE LOS MUSCULOS LISOS QUE INCLUYEN, PERO QUE NO ESTAN LIMITADAS, LOS ESPASMOS DEL ESFINTER DE LA ARTERIOLA CARDIOVASCULAR, DEL SISTEMA GASTROINTESTINAL, DEL SISTEMA URINARIO, DE LA VEJIGA Y DEL RECTO, EL METODO COMPRENDE LA ADMINISTRACION AL PACIENTE QUE SUFRA DE TALES DESORDENES DE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE TOXINA DE BOTULINUM SELECCIONADA DE ENTRE EL GRUPO QUE CONSTA DE TOXINA DE BOTULINUM DE LOS TIPOS B, C, D, E, F Y G.
ES95906674T 1993-12-28 1994-12-16 Toxinas botulinicas para el tratamiento de la hiperhidrosis. Expired - Lifetime ES2159624T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17399693A 1993-12-28 1993-12-28

Publications (1)

Publication Number Publication Date
ES2159624T3 true ES2159624T3 (es) 2001-10-16

Family

ID=22634387

Family Applications (18)

Application Number Title Priority Date Filing Date
ES97200028T Expired - Lifetime ES2163090T3 (es) 1993-12-28 1994-12-16 Uso de toxina botulinica para tratar la cefalea tensional.
ES99203920T Expired - Lifetime ES2207910T5 (es) 1993-12-28 1994-12-16 Toxinas botulinicas para modular las secreciones controladas por el sistema colinergico.
ES05018368T Expired - Lifetime ES2334357T3 (es) 1993-12-28 1994-12-16 Uso del componente neurotoxico de toxinas botulinicas para el tratamiento de un musculo espastico.
ES07002714T Expired - Lifetime ES2309973T3 (es) 1993-12-28 1994-12-16 Uso de toxina botulinica para la fabricacion de un medicamento para reducir el dolor en la parte baja de la espalda.
ES04019047T Expired - Lifetime ES2247575T3 (es) 1993-12-28 1994-12-16 Componente neurotoxico de la toxina botulinica para modular las secreciones controladas por el sistema colinergico.
ES03015589T Expired - Lifetime ES2242126T3 (es) 1993-12-28 1994-12-16 Uso del componente neurotoxico de la toxina botulinica para tratar el dolor asociado a la musculatura.
ES03015590T Expired - Lifetime ES2251651T3 (es) 1993-12-28 1994-12-16 Uso del componente neurotoxico de la toxina botulinica para tratar los espasmos musculares.
ES01118793T Expired - Lifetime ES2355491T3 (es) 1993-12-28 1994-12-16 Uso de toxinabotulínica tipo b para la fabricación de un medicamento para el tratamiento de espasmos musculares.
ES05016177T Expired - Lifetime ES2340172T3 (es) 1993-12-28 1994-12-16 Uso del componente neurotoxico de la toxina botulinica para tratar el dolor asociado con la distonia cervical.
ES99203735T Expired - Lifetime ES2237033T5 (es) 1993-12-28 1994-12-16 Toxinas botulinicas a para tratar dolor asociado con espasmos de los musculos lisos.
ES00203421T Expired - Lifetime ES2223393T3 (es) 1993-12-28 1994-12-16 Toxinas botulinicas para tratar dolor asociado con transtornos musculares.
ES01118792T Expired - Lifetime ES2319860T3 (es) 1993-12-28 1994-12-16 Uso de toxina botulinica de tipo b para la fabricacion de un medicamento para reducir el dolor asociado a un trastorno muscular.
ES05018367T Expired - Lifetime ES2339865T3 (es) 1993-12-28 1994-12-16 Uso del componente neurotoxico de toxinas botulinicas para el tratamiento de musculos espasticos.
ES00203294T Expired - Lifetime ES2246800T3 (es) 1993-12-28 1994-12-16 Toxina botulinica para tratar la distonia.
ES95906674T Expired - Lifetime ES2159624T3 (es) 1993-12-28 1994-12-16 Toxinas botulinicas para el tratamiento de la hiperhidrosis.
ES08017803T Expired - Lifetime ES2347384T3 (es) 1993-12-28 1994-12-16 Componente neurotoxico de una toxina botulinica para tratar de discinesia tardia.
ES04019048T Expired - Lifetime ES2248780T3 (es) 1993-12-28 1994-12-16 Componente neurotoxico de toxinas botulinicas para tratar la distonia cervical.
ES04019046T Expired - Lifetime ES2332905T3 (es) 1993-12-28 1994-12-16 Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos.

Family Applications Before (14)

Application Number Title Priority Date Filing Date
ES97200028T Expired - Lifetime ES2163090T3 (es) 1993-12-28 1994-12-16 Uso de toxina botulinica para tratar la cefalea tensional.
ES99203920T Expired - Lifetime ES2207910T5 (es) 1993-12-28 1994-12-16 Toxinas botulinicas para modular las secreciones controladas por el sistema colinergico.
ES05018368T Expired - Lifetime ES2334357T3 (es) 1993-12-28 1994-12-16 Uso del componente neurotoxico de toxinas botulinicas para el tratamiento de un musculo espastico.
ES07002714T Expired - Lifetime ES2309973T3 (es) 1993-12-28 1994-12-16 Uso de toxina botulinica para la fabricacion de un medicamento para reducir el dolor en la parte baja de la espalda.
ES04019047T Expired - Lifetime ES2247575T3 (es) 1993-12-28 1994-12-16 Componente neurotoxico de la toxina botulinica para modular las secreciones controladas por el sistema colinergico.
ES03015589T Expired - Lifetime ES2242126T3 (es) 1993-12-28 1994-12-16 Uso del componente neurotoxico de la toxina botulinica para tratar el dolor asociado a la musculatura.
ES03015590T Expired - Lifetime ES2251651T3 (es) 1993-12-28 1994-12-16 Uso del componente neurotoxico de la toxina botulinica para tratar los espasmos musculares.
ES01118793T Expired - Lifetime ES2355491T3 (es) 1993-12-28 1994-12-16 Uso de toxinabotulínica tipo b para la fabricación de un medicamento para el tratamiento de espasmos musculares.
ES05016177T Expired - Lifetime ES2340172T3 (es) 1993-12-28 1994-12-16 Uso del componente neurotoxico de la toxina botulinica para tratar el dolor asociado con la distonia cervical.
ES99203735T Expired - Lifetime ES2237033T5 (es) 1993-12-28 1994-12-16 Toxinas botulinicas a para tratar dolor asociado con espasmos de los musculos lisos.
ES00203421T Expired - Lifetime ES2223393T3 (es) 1993-12-28 1994-12-16 Toxinas botulinicas para tratar dolor asociado con transtornos musculares.
ES01118792T Expired - Lifetime ES2319860T3 (es) 1993-12-28 1994-12-16 Uso de toxina botulinica de tipo b para la fabricacion de un medicamento para reducir el dolor asociado a un trastorno muscular.
ES05018367T Expired - Lifetime ES2339865T3 (es) 1993-12-28 1994-12-16 Uso del componente neurotoxico de toxinas botulinicas para el tratamiento de musculos espasticos.
ES00203294T Expired - Lifetime ES2246800T3 (es) 1993-12-28 1994-12-16 Toxina botulinica para tratar la distonia.

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES08017803T Expired - Lifetime ES2347384T3 (es) 1993-12-28 1994-12-16 Componente neurotoxico de una toxina botulinica para tratar de discinesia tardia.
ES04019048T Expired - Lifetime ES2248780T3 (es) 1993-12-28 1994-12-16 Componente neurotoxico de toxinas botulinicas para tratar la distonia cervical.
ES04019046T Expired - Lifetime ES2332905T3 (es) 1993-12-28 1994-12-16 Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos.

Country Status (8)

Country Link
EP (23) EP1790352B1 (es)
JP (33) JP3238154B2 (es)
AU (1) AU688452B2 (es)
CA (2) CA2682117A1 (es)
DE (23) DE69435194D1 (es)
ES (18) ES2163090T3 (es)
FR (1) FR08C0034I1 (es)
WO (1) WO1995017904A2 (es)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
DE69435254D1 (de) 1993-06-10 2009-12-31 Allergan Inc Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
AU2007202480B2 (en) * 1993-12-28 2009-01-29 Allergan, Inc. Method for treating pain associated with a muscle disorder
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
EP1790352B1 (en) * 1993-12-28 2008-07-09 Allergan, Inc. Use of botulinum toxin for the manufacture of a medicament for reducing low back pain
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
PT1086702E (pt) * 1994-05-09 2005-08-31 William J Binder Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6699966B1 (en) 1996-07-08 2004-03-02 University Of Massachusetts Proteins within the type E botulinum neurotoxin complex
US6780413B2 (en) 1996-09-19 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders
AU2006225231B2 (en) * 1997-07-15 2006-12-07 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
AU2008201535C1 (en) * 1997-07-15 2013-09-12 Allergan, Inc. Use of neurotoxin therapy for treatment of urologic and related disorders
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
EP1475099B2 (en) 1997-07-15 2014-04-09 The Regents of the University of Colorado Use of botulinum toxin to treat urinary incontinence
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
JP2002501033A (ja) 1998-01-26 2002-01-15 ユニバーシティー オブ マサチューセッツ Ａ型ボツリヌス菌の生物学的活性赤血球凝集素とその使用法
US8790897B2 (en) 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
GB9818548D0 (en) * 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6977080B1 (en) * 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6328977B1 (en) * 2000-02-22 2001-12-11 Allergan Sales, Inc. Method for treating hyperparathyroidism
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
AU2001276005A1 (en) * 2000-08-02 2002-02-13 Allergan Sales, Inc. Method for treating a neoplasm
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6827931B1 (en) * 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
ITUD20010002A1 (it) 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
GB0111146D0 (en) * 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
KR20030018827A (ko) * 2001-08-31 2003-03-06 서구일 Ａ형 보툴리눔 독소를 유효성분으로 포함하는 신경차단제,및 이를 이용한 교감신경절 차단의 적응질환 치료제
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US6776991B2 (en) 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20040115139A1 (en) * 2002-10-15 2004-06-17 Allergan, Inc. Botulinum toxin dental therapies and procedures
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
ZA200506715B (en) * 2003-03-06 2007-05-30 Botulinum Toxin Res Ass Inc Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
BRPI0408114A (pt) 2003-03-06 2006-03-01 Botulinum Toxin Res Ass Inc tratamento de calázio crÈnico e hordéolo com toxina botulinìca
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
FR2857595B1 (fr) * 2003-07-18 2005-10-07 Sod Conseils Rech Applic Utilisation de toxine botulique pour preparer un medicament destine a prevenir ou traiter les troubles sonores lies a l'agonie
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
DE602005001854T2 (de) * 2004-02-12 2008-04-17 Philip San Clemente Radovic Behandlung von abweichungen der ersten metatarsophalangealen verbindung des fusses
US7276244B2 (en) 2004-02-12 2007-10-02 Philip Radovic Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
JP2007527431A (ja) 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
ES2691498T3 (es) 2004-03-03 2018-11-27 Revance Therapeutics, Inc. Aplicación tópica y liberación transdérmica de toxinas botulínicas
EP1861112A4 (en) 2005-03-03 2009-07-22 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINES
EP1747782A1 (en) 2005-07-19 2007-01-31 Cesare Montecucco Products for topical application comprising lysophospholipids and fatty acids
US7910116B2 (en) 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
CA2629499A1 (en) 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US7655625B2 (en) 2006-02-13 2010-02-02 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US7811586B2 (en) 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
US8002717B2 (en) 2007-03-30 2011-08-23 Anders Fagergren Quantification of mechanical and neural contributions to spasticity
BRPI0813627B1 (pt) 2007-07-26 2021-09-14 Revance Therapeutics, Inc Composição farmacêutica ou cosmética compreendendo um peptídeo catiônico e kit para administração da mesma
EP2072039A1 (en) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
US8470337B2 (en) 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
LT2379104T (lt) 2008-12-31 2018-04-10 Revance Therapeutics, Inc. Injekcinės botulino toksino vaisto formos
BRPI1015938A2 (pt) 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
RU2545453C2 (ru) * 2013-03-21 2015-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения переломов нижней челюсти
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
WO2016002984A1 (ko) * 2014-06-30 2016-01-07 (주)메디톡스 보툴리눔 독소를 유효성분으로 포함하는 골관절염 치료용 약제학적 조성물 및 그를 이용한 골관절염 치료 방법
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
RU2762607C2 (ru) 2016-09-13 2021-12-21 Аллерган, Инк. Стабилизированные небелковые композиции клостридиального токсина
WO2020047159A1 (en) * 2018-08-28 2020-03-05 Ira Sanders Skin therapeutics
RU2732204C1 (ru) * 2020-01-28 2020-09-14 Частное учреждение образовательная организация высшего образования "Медицинский университет "Реавиз" Способ лечения головных болей напряжения по Гурову-Левину
US20230365957A1 (en) * 2020-10-07 2023-11-16 Pro-Tox Inc. Vacuum drying method for botulinum toxin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
GB9022250D0 (en) * 1990-10-12 1990-11-28 Glaxo Group Ltd Medicaments
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
JP3510886B2 (ja) * 1992-06-23 2004-03-29 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド ボツリヌスｂ複合体を含有する医薬組成物
AU6030494A (en) * 1993-01-15 1994-08-15 Associated Synapse Biologics Method for treating myofascial pain syndrome
CA2164626C (en) * 1993-06-10 2004-11-23 K. Roger Aoki Multiple botulinum toxins for treating neuromuscular disorders and conditions
DE69435254D1 (de) * 1993-06-10 2009-12-31 Allergan Inc Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
EP1790352B1 (en) * 1993-12-28 2008-07-09 Allergan, Inc. Use of botulinum toxin for the manufacture of a medicament for reducing low back pain
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
PT1086702E (pt) * 1994-05-09 2005-08-31 William J Binder Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
JP2001104991A (ja) * 1999-10-12 2001-04-17 Toyoaki Kubota 循環水の有機質除去剤

Also Published As

Publication number Publication date
EP1103267B1 (en) 2004-09-15
CA2180011A1 (en) 1995-07-06
DE69434535T2 (de) 2006-07-20
EP0770395B1 (en) 2001-10-24
CA2682117A1 (en) 1995-07-06
DE122008000042I1 (de) 2009-01-02
EP1488803A1 (en) 2004-12-22
ES2246800T3 (es) 2006-03-01
EP1598077A1 (en) 2005-11-23
EP1757325A1 (en) 2007-02-28
JP2002087984A (ja) 2002-03-27
JP2008056683A (ja) 2008-03-13
JP2002068989A (ja) 2002-03-08
ES2355491T3 (es) 2011-03-28
JP2002097145A (ja) 2002-04-02
JP2012167116A (ja) 2012-09-06
JP2002087988A (ja) 2002-03-27
EP0737074B1 (en) 2001-08-01
ES2332905T3 (es) 2010-02-15
DE69434610T2 (de) 2008-11-27
EP1010431A2 (en) 2000-06-21
DE69428813D1 (de) 2001-11-29
EP1103267A1 (en) 2001-05-30
EP1598077B1 (en) 2009-11-04
EP1421948B1 (en) 2008-10-08
DE69435276D1 (de) 2010-04-08
EP1790352B1 (en) 2008-07-09
DE69433394T2 (de) 2004-10-14
DE69435302D1 (de) 2010-08-26
JP2010202660A (ja) 2010-09-16
EP1563843B1 (en) 2013-08-07
ES2334357T3 (es) 2010-03-09
JP2010209105A (ja) 2010-09-24
EP1366770B1 (en) 2005-07-27
EP1421948A2 (en) 2004-05-26
EP1790352A1 (en) 2007-05-30
FR08C0034I1 (fr) 2008-09-26
ES2339865T3 (es) 2010-05-26
EP1366770A3 (en) 2004-03-17
JP2008056682A (ja) 2008-03-13
EP1600163A1 (en) 2005-11-30
DE69434610D1 (de) 2008-08-21
ES2248780T3 (es) 2008-06-16
EP1010431B2 (en) 2010-07-14
DE69434443T2 (de) 2006-05-24
ES2319860T3 (es) 2009-05-14
JP2006160755A (ja) 2006-06-22
DE69434319T3 (de) 2011-02-17
WO1995017904A3 (en) 1995-10-19
EP1591129A2 (en) 2005-11-02
ES2207910T3 (es) 2004-06-01
EP1005867B1 (en) 2003-12-03
EP1366771B1 (en) 2008-03-26
DE69435116D1 (de) 2008-08-21
EP1477183A1 (en) 2004-11-17
EP0770395A1 (en) 1997-05-02
AU1516295A (en) 1995-07-17
JP2002104991A (ja) 2002-04-10
EP1477183B1 (en) 2005-11-02
JP2008037877A (ja) 2008-02-21
HK1072375A1 (en) 2005-08-26
DE69435321D1 (de) 2010-12-16
DE69434008D1 (de) 2004-10-21
EP1591129A3 (en) 2005-11-16
EP1147775B1 (en) 2009-03-04
EP1072270A3 (en) 2002-08-07
JP3238154B2 (ja) 2001-12-10
DE69435270D1 (de) 2010-04-01
HK1064599A1 (en) 2005-02-04
EP1488803B1 (en) 2008-03-26
JP2006160753A (ja) 2006-06-22
ES2242126T3 (es) 2005-11-01
JP2012167115A (ja) 2012-09-06
CA2180011C (en) 2001-05-15
JP2002097156A (ja) 2002-04-02
JP2006160754A (ja) 2006-06-22
ES2207910T5 (es) 2010-05-21
DE69434535D1 (de) 2005-12-08
EP1005867B2 (en) 2010-02-17
JP2012197287A (ja) 2012-10-18
EP1010431B1 (en) 2005-03-30
EP1366770A2 (en) 2003-12-03
JP2013006865A (ja) 2013-01-10
DE122009000038I1 (de) 2009-11-05
JP2007262086A (ja) 2007-10-11
EP1563843A1 (en) 2005-08-17
EP1005867A3 (en) 2001-06-13
AU688452B2 (en) 1998-03-12
DE69434540T2 (de) 2009-06-18
DE69434319D1 (de) 2005-05-04
EP2027872B1 (en) 2010-07-14
ES2223393T3 (es) 2005-03-01
EP1010431A3 (en) 2001-05-16
DE69435249D1 (de) 2009-12-17
DE69435194D1 (de) 2009-04-16
EP1072270B1 (en) 2005-10-19
JP2002114706A (ja) 2002-04-16
DE69433394T3 (de) 2010-08-12
ES2237033T5 (es) 2010-10-29
DE69434511D1 (de) 2006-03-02
EP2027872A1 (en) 2009-02-25
EP1072270A2 (en) 2001-01-31
ES2347384T3 (es) 2010-10-28
DE69435149D1 (de) 2008-11-20
JP2012188433A (ja) 2012-10-04
DE69435243D1 (de) 2009-11-19
EP1591129B1 (en) 2010-02-24
EP1147775A2 (en) 2001-10-24
JP2008063339A (ja) 2008-03-21
ES2309973T3 (es) 2008-12-16
JP2006160756A (ja) 2006-06-22
HK1071071A1 (en) 2005-07-08
DE69433394D1 (de) 2004-01-15
ES2340172T3 (es) 2010-05-31
DE69434008T2 (de) 2005-09-22
ES2251651T3 (es) 2008-07-16
JP2010202659A (ja) 2010-09-16
EP1502600A1 (en) 2005-02-02
EP1005867A2 (en) 2000-06-07
DE122008000043I1 (de) 2008-11-20
DE69434319T2 (de) 2006-03-09
JP2012167117A (ja) 2012-09-06
ES2247575T3 (es) 2006-03-01
JP2002104990A (ja) 2002-04-10
EP1366771A3 (en) 2003-12-10
DE69428813T2 (de) 2002-04-04
HK1106700A1 (en) 2008-03-20
JP2002087987A (ja) 2002-03-27
JP2008031176A (ja) 2008-02-14
DE69434511T2 (de) 2006-07-13
EP1486214A1 (en) 2004-12-15
ES2237033T3 (es) 2005-07-16
JP2010202661A (ja) 2010-09-16
JP2012167114A (ja) 2012-09-06
DE69434443D1 (de) 2005-09-01
EP1600163B1 (en) 2010-02-17
ES2163090T3 (es) 2002-01-16
JP2002087986A (ja) 2002-03-27
DE69435330D1 (de) 2011-01-27
EP1147776A2 (en) 2001-10-24
HK1033274A1 (en) 2001-08-24
EP1602379A1 (en) 2005-12-07
EP1147776B1 (en) 2010-12-15
DE69434540D1 (de) 2009-03-26
EP1147776A3 (en) 2003-01-15
HK1070831A1 (en) 2005-06-30
EP1421948A3 (en) 2004-06-16
DE69427869T2 (de) 2002-04-11
EP1366771A2 (en) 2003-12-03
EP1502600B1 (en) 2009-10-07
EP0737074A1 (en) 1996-10-16
EP1757325B1 (en) 2010-11-03
DE69427869D1 (de) 2001-09-06
WO1995017904A2 (en) 1995-07-06
JPH09507234A (ja) 1997-07-22
EP1147775A3 (en) 2003-01-15
JP2002087985A (ja) 2002-03-27

Similar Documents

Publication Publication Date Title
ES2159624T3 (es) Toxinas botulinicas para el tratamiento de la hiperhidrosis.
CY1108065T1 (el) Χρηση βοτουλινικης τοξινης για την παρασκευη ενος φαρμακου για περιφερικη χορηγηση για θεραπεια πονου που δεν σχετιζεται με μυϊκο σπασιμο ή πονοκεφαλο
BR0114440A (pt) Métodos para tratamento de lesão muscular
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
ES2191192T3 (es) Tienopirimidinas.
NO20013727L (no) Anvendelse av Botulinumtoksin B for fremstilling av et medikament
MX9301847A (es) Aminas biciclicas-heterociclicas farmaceuticamente activas
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ES2194025T3 (es) Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares.
ES2196092T3 (es) Composicion antibacteriana liposomica, de baja rigidez.
ES2194918T3 (es) Compuestos de tiazol y tiadiazol como ligando receptor de dopamina d3.
ES2156107T3 (es) Un fgf-4 no glicosilado y composiciones que lo contienen.
EA200300560A1 (ru) Улучшенный способ лечения
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
EP0869801A4 (en) THERAPEUTIC AND DIAGNOSTIC AGENTS FOR TREATING MICROBIAL INFECTIONS
EA199800866A1 (ru) Способ снятия боли
PT762883E (pt) Piridilbisfosfonatos utilizaveis como agentes terapeuticos
ES2130506T3 (es) Uso de 5-acil-1,4-dihidropiridinas para tratamiento de enfermedades del snc.
CO4230094A1 (es) Composiciones
ES2196171T3 (es) Agentes antitumorales de tioxantenona liofilizada.
AR022348A1 (es) Una composicion farmaceutica para el tratamiento de los sintomas del tracto urinario inferior
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
DK0872239T3 (da) Anvendelse af olanzapin til fremstilling af et lægemiddel til behandling af cerebral fokal iskæmi
EP0182569A3 (en) Use of 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyridoû1,2-a¨pyrimidine-3-carboxamide for the prevention and treatment of gastrointestinal damages
ES2166912T3 (es) Composiciones, que comprenden bismuto y uno o mas agentes antimicrobianos, para el tratamiento y prevencion de trastornos gastrointestinales.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 737074

Country of ref document: ES